Internal Reference Number: FOI_9371
Date Request Received: 28/04/2026 00:00:00
Date Request Replied To: 07/05/2026 00:00:00
This response was sent via: By Email
Request Summary: GLP1s OGDs
Request Category: Health
| Question Number 1: I am writing to request information under the Freedom of Information Act 2000 regarding your Trust鈥檚 guidance and practice relating to the management of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) prior to upper gastrointestinal endoscopy (oesophago-gastro-duodenoscopy, OGD). Clarification This request relates only to adult elective OGD procedures and excludes colonoscopy or other endoscopic procedures unless included within a shared protocol. Information Requested Guidance Availability a) Does your Trust have any guidance, protocol, or policy relating to the management of GLP-1 receptor agonists prior to OGD? b) If yes, please provide: 鈥傗�傗�傗�傗�傗�傗�⑩�傗�傗�傗�傗�侫 copy of the guidance, or 鈥傗�傗�傗�傗�傗�傗�⑩�傗�傗�傗�傗�侫 link to where it is publicly available | |
| Answer To Question 1: Pre-operative Assessment follow the current local hospital policy, to continue GLP-1 receptor agonists. The anaesthetist takes airway/intubation precautions. Ozempic and Wegovy have a half life of 7 days and can be in the patient's system for 5 to 6 weeks. Please see 鈥淧re-operative Medication in Fasted Patients - stopping drugs before surgery鈥�. Please use the following link to locate the Guidelines as follows; https://app.eolasmedical.com/auto-login/EOLAS%23ORG%23staging-salisbury-nhs-foundation-trust%231120b4c7-8856-4520-934a-f2778c95fc7a%23860230f5-00eb-4248-8db4-c71d458f6f81 SA国际传媒 > Hospital Guidelines > Adult Surgery > Preoperative Guidance > Pre-operative Medication in Fasted Patients - stopping drugs before surgery Response from Endoscopy: We don't have any specific policies for GLP-1 RAs. The use of these drugs in Endoscopy has not been discussed, reviewed or audited. | |
| Question Number 2: Medication Management a) What is your Trust鈥檚 recommendation regarding oral GLP-1 receptor agonists prior to OGD? (e.g. continue, omit morning dose, withhold for a defined period) b) What is your Trust鈥檚 recommendation regarding injectable GLP-1 receptor agonists prior to OGD? | |
| Answer To Question 2: N/A 鈥� we do not have a Trust recommendation regarding GLP-1 receptor agonists prior to OGD. | |
| Question Number 3: Indication-Specific Guidance a) Does your Trust differentiate guidance based on indication (e.g. diabetes vs obesity)? b) If yes, please outline how recommendations differ. | |
| Answer To Question 3: N/A 鈥� the Trust does not have guidance for GLP1 RAs for OGD. | |
| Question Number 4: Fasting Protocol a) Does your Trust modify fasting instructions for patients taking GLP-1 receptor agonists prior to OGD? b) If yes, please provide details of the modified fasting protocol. | |
| Answer To Question 4: No, we do not modify fasting instructions for patients taking GLP-1 RA prior to OGD. | |
| Question Number 5: Operational Impact a) Has your Trust identified any impact of GLP-1 receptor agonist use on OGD procedures (e.g. cancellations, retained gastric contents, aspiration risk)? b) If recorded, please provide any available data or summary information. | |
| Answer To Question 5: No, the Trust has not identified any impact of GLP-1 RA use on OGD procedures. | |
| Question Number 6: Governance a) Has the management of GLP-1 receptor agonists in endoscopy been discussed, reviewed, or audited within your Trust? | |
| Answer To Question 6: The use of these drugs in Endoscopy has not been discussed, reviewed or audited. | |
| To return to the list of all the FOI requests please click here |
Our staff at SA国际传媒 Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
